| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Erlotinib | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | Tipifarnib | GDSC1000 | pan-cancer | AAC | -0.0083 | 0.8 |
| mRNA | PIK-93 | GDSC1000 | pan-cancer | AAC | -0.0065 | 0.8 |
| mRNA | Vandetanib | FIMM | pan-cancer | AAC | -0.042 | 0.8 |
| mRNA | avicin D | CTRPv2 | pan-cancer | AAC | -0.013 | 0.8 |
| mRNA | FMK | GDSC1000 | pan-cancer | AAC | 0.0084 | 0.8 |
| mRNA | alisertib:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0081 | 0.8 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | -0.0075 | 0.8 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | -0.012 | 0.8 |
| mRNA | GW843682X | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |